For active psoriatic arthritis (PsA)
The first injection should be given under the supervision of a healthcare professional. A patient may self-inject HUMIRA after appropriate training and monitoring by a healthcare professional.
Instruct patients to rotate injection sites and not to inject into areas where the skin is tender, bruised, red, or hard.
In clinical trials, injection site reactions (erythema and/or itching, hemorrhage, pain, or swelling) were reported in 20% of HUMIRA-treated patients vs 14% of placebo-treated patients. Most reactions were mild and did not require discontinuation.
The most common adverse reactions in HUMIRA clinical trials (incidence >10%) were: infections (eg, upper respiratory, sinusitis), injection site reactions, headache, and rash.
No citrate buffers, thinner needle, less pain immediately following injection compared with the HUMIRA 40 mg/0.8 mL presentation.2†‡
†HUMIRA Citrate-free is available to all indicated patients in the United States. HUMIRA Citrate-free features the same safety and efficacy profile of HUMIRA you've come to count on.
*No special starting dosing required.
‡Injection site pain immediately following injection as measured using a 0-10 cm Visual Analog Scale: HUMIRA 40 mg/0.4 mL vs HUMIRA 40 mg/0.8 mL.
EOW=every other week